We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+5.51%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$1.01B
AUM Growth
+$183M
Cap. Flow
+$156M
Cap. Flow %
15.54%
Top 10 Hldgs %
13.85%
Holding
515
New
136
Increased
129
Reduced
153
Closed
95

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$26.6M
2
ETG
Eaton Vance Tax-Advantaged Global Dividend Income Fund
ETG
+$6.51M
3
CSQ icon
Calamos Strategic Total Return Fund
CSQ
+$6.38M
4
RQI icon
Cohen & Steers Quality Income Realty Fund
RQI
+$6.36M
5
CHI
Calamos Convertible Opportunities and Income Fund
CHI
+$6.34M

Top Sells

Rank Stock Value
1
RVT icon
Royce Value Trust
RVT
+$5.55M
2
EMD
Western Asset Emerging Markets Debt Fund
EMD
+$5.07M
3
GGN
GAMCO Global Gold, Natural Resources & Income Trust
GGN
+$4.96M
4
FAX
abrdn Asia-Pacific Income Fund
FAX
+$4.79M
5
IGD
Voya Global Equity Dividend and Premium Opportunity Fund
IGD
+$4.64M

Sector Composition

Rank Sector Weight
1 Technology 17.19%
2 Industrials 12.17%
3 Financials 11.38%
4 Healthcare 10.07%
5 Consumer Discretionary 8.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GCI
301
DELISTED
Gannett Co., Inc
GCI
$1.1M 0.11%
130,928
-2,475
-2% -$22.1K
ONC
302
BeOne Medicines Ltd
ONC
$38.7B
$1.09M 0.11%
29,746
+4,788
+19% +$174K
MRK icon
303
Merck
MRK
$318B
$1.06M 0.11%
17,504
+2,416
+16% +$147K
JUNO
304
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.05M 0.1%
47,376
+7,896
+20% +$169K
V icon
305
Visa
V
$677B
$1.05M 0.1%
9,512
+6,115
+180% +$526K
SYKE
306
DELISTED
SYKES Enterprises Inc
SYKE
$1.03M 0.1%
35,035
-4,578
-12% -$131K
AZN icon
307
AstraZeneca
AZN
$250B
$1.03M 0.1%
16,493
+3,164
+24% +$184K
WFC icon
308
Wells Fargo
WFC
$264B
$1.01M 0.1%
+14,544
New +$825K
CLW icon
309
Clearwater Paper
CLW
$376M
$978K 0.1%
17,464
-12,087
-41% -$715K
IOVA icon
310
Iovance Biotherapeutics
IOVA
$2.83B
$935K 0.09%
125,536
+20,920
+20% +$153K
NVS icon
311
Novartis
NVS
$297B
$925K 0.09%
13,902
+2,223
+19% +$148K
AXE
312
DELISTED
Anixter International Inc
AXE
$910K 0.09%
+11,480
New +$937K
ADXS
313
DELISTED
Advaxis Inc
ADXS
$890K 0.09%
7,263
+1,211
+20% +$157K
DBI icon
314
Designer Brands
DBI
$333M
$889K 0.09%
42,972
-2,835
-6% -$58.8K
TCRT icon
315
Alaunos Therapeutics
TCRT
$4.86M
$875K 0.09%
920
+153
+20% +$142K
FLOW
316
DELISTED
SPX FLOW, Inc.
FLOW
$861K 0.09%
24,798
-52,746
-68% -$1.8M
SPG icon
317
Simon Property Group
SPG
$72.3B
$857K 0.09%
4,979
-2,803
-36% -$501K
CLDX icon
318
Celldex Therapeutics
CLDX
$3.27B
$852K 0.08%
15,737
+2,623
+20% +$137K
KDNY
319
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$850K 0.08%
15,809
+2,634
+20% +$149K
CRIS icon
320
Curis
CRIS
$7.83M
$845K 0.08%
152
+28
+23% +$156K
INO icon
321
Inovio Pharmaceuticals
INO
$69M
$843K 0.08%
10,615
+1,769
+20% +$141K
MGNX icon
322
MacroGenics
MGNX
$257M
$837K 0.08%
44,983
+7,496
+20% +$145K
XNCR icon
323
Xencor
XNCR
$1.55B
$828K 0.08%
34,624
+5,768
+20% +$139K
BMY icon
324
Bristol-Myers Squibb
BMY
$132B
$826K 0.08%
15,192
+2,532
+20% +$139K
ICLR icon
325
Icon
ICLR
$12.7B
$785K 0.08%
9,845
-493
-5% -$40.4K
11 12
13
14 15

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q1 2017 Portfolio in Review

As of Q1 2017, Vident Investment Advisory held 515 positions worth $1.01B, up 22% from $824M the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Vident Investment Advisory deployed $156M of net new capital in Q1 2017, opening 136 new positions and adding to 129 existing holdings. Its largest new stake was Eaton Vance Tax-Advantaged Global Dividend Income Fund: 428,405 shares worth $6.71M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Virtus Convertible & Income Fund, an estimated $3.84M trimmed.

  • Vident Investment Advisory's largest Q1 2017 buy was Eaton Vance Tax-Advantaged Global Dividend Income Fund: 428,405 shares worth $6.71M.
  • Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q1 2017, an estimated $26.6M increase.
  • Vident Investment Advisory's biggest Q1 2017 reduction was Virtus Convertible & Income Fund, cutting an estimated $3.84M.
  • Vident Investment Advisory fully exited Royce Value Trust in Q1 2017, selling an estimated $5.55M.
  • Vident Investment Advisory's ten largest holdings make up 14% of its $1.01B portfolio in Q1 2017.
  • Vident Investment Advisory opened 136 new positions and closed 95 in Q1 2017.
  • Vident Investment Advisory's portfolio value rose 22% quarter-over-quarter to $1.01B.

Based on Vident Investment Advisory's 13F filing for Q1 2017, filed 10 May 2017.